Evaluation of the therapeutic effect of a combination drug including Apocynin, Niacin, and Tannin on COVID-19

Phase 2

Recruiting

• Conditions: COVID-19-induced pneumonia.; COVID-19; U07.01

• Registration Number: IRCT20200418047122N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Age more than 18 years
Clinical and paraclinical signs and symptoms for COVID19-induced pneumonia
inpatient setting
Positive PCR for COVID19
Informed consent

Exclusion Criteria

Pregnancy
A recent medical history of using ACEI and ARB drugs, fludrocortisone, spironolactone, eplerenone, TCA antidepressant, Simvastatin, MAO inhibitors, serotonin inhibitors such as sertraline and citalopram, Triptamins, Alcoholism
Heart Failure (EF<25%)
Hepatic failure (Child Pugh score = C ,AST> 5 times of the upper limit normal)
Severe renal dysfunction (GFR less than 30cc per min)
Any drug side-effects including: Patients’ intolerance, Diarrhea, Gastrointestinal problems
Active peptic ulcer
Active Bleeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: BID. Method of measurement: Thermometer.;Hemodynamic signs. Timepoint: BID. Method of measurement: P/E.;O2 sat. Timepoint: BID. Method of measurement: Puls-Oximetery.;Clinical symptomes. Timepoint: TDS. Method of measurement: P/E and medical hx.

Secondary Outcome Measures

Name	Time	Method
Drug side-effects. Timepoint: Continuous. Method of measurement: PE and MH.;Survival and clinical symptoms. Timepoint: Continuous. Method of measurement: PE and MH.